about
Detectable clonal mosaicism and its relationship to aging and cancerImputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesPHC3, a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumorsAddition of pamidronate to chemotherapy for the treatment of osteosarcomaEvaluation of eIF4E expression in an osteosarcoma-specific tissue microarrayGenome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcomaOsteosarcoma: Current Treatment and a Collaborative Pathway to SuccessChildren's Oncology Group's 2013 blueprint for research: bone tumorsDickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathwayA summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW FoundationA RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer CellsGenome-wide association study identifies two susceptibility loci for osteosarcomaMethotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good RQuantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrierHigh P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura.Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective.Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma.Cell proliferation of cultured human cancer cells are affected by the elevated tumor pressures that exist in vivo.Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model.Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.Toward a drug development path that targets metastatic progression in osteosarcoma.Initial testing of topotecan by the pediatric preclinical testing program.Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.Intrinsic and acquired resistance to methotrexate in acute leukemia.Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramInitial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of temozolomide by the pediatric preclinical testing programInitial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
P50
Q23916196-9AB8978B-6A95-4952-967C-0F66C6BC4E1AQ23924183-261E441C-E3DD-4539-B673-9701AF1DD7B3Q24170413-A017E768-D4BC-492B-924D-0937E7A4E2ABQ24304471-EDCFCACD-11C9-4C16-AB29-19D9A1C8E493Q24594269-7962EB7F-626A-4D28-AF03-322EDFA6B4CEQ24635844-D2E38A1F-78A4-47B6-BE82-E59CE57AAC0DQ24801656-5A5E5EC9-6B0F-4151-9DF1-6EA9488770D8Q26797555-AF90DEF1-A09F-4AB3-A616-5EBD257B4F03Q27027664-D1119339-72AC-413C-9F75-D083DB662AFDQ28256833-6458DE55-AE78-4DE3-8669-B5B51FF6E411Q28386370-301C44FE-57EA-45FF-B76E-C2A50F0828B5Q28550430-19B308D4-8AE7-46BC-B843-CCE72C40D63AQ28659642-F41242B2-E91A-4DB0-9084-7700C18E3F4DQ30357731-1F0EC386-F4A3-4467-AAA9-6AC30C19B31FQ33331479-2792DC59-BD1C-453A-9292-FA2C44AC79D3Q33343771-43F631AC-61EF-4334-BBD9-055FDCF114D1Q33349428-CAE0DFED-D301-4DB5-B7E1-3CD4F2862429Q33392318-67618C04-B9B9-499E-9799-E6EAC89FA296Q33402047-25466890-B889-4F80-8A66-2B64C82AD350Q33433095-D9FBB63A-D7E2-4A77-B65A-23FB5769D8ABQ33433953-5B23A867-B61E-441C-8780-EAE139CCBB2DQ33434899-FA4A0186-DD98-49E9-B4C1-023DABAEB479Q33559539-EFAC2B13-CE58-4624-88B1-88A4F853B8D7Q33579181-E2A10B73-889A-4193-8B14-62AB5E65CCEAQ33867046-DC9DB31A-D3C7-4A47-B1CC-6FBCDC2EAC92Q33872384-ED7A802C-D111-47A7-A94A-8D29F2E7F9B4Q34052760-AB83C66A-D1AD-4943-AF83-B2665F1A2C13Q34073784-D7C6E5AA-51D7-43DC-B9FF-37837C8CE94AQ34110523-35D57EB9-5103-4079-B6C4-67C306158DE2Q34249719-C132C545-D712-4D0F-B0A9-036989FD7AE6Q34361391-6945E885-137F-4605-85C7-294E93C8D68CQ34371357-672D3A27-C794-417E-8B54-67CCCF22FF41Q34395818-EC95B3D5-548A-4527-8CFE-34DEABC13D54Q34414710-D9349CE2-15DD-481E-84C9-F8B9061E03B8Q34414736-73376DD3-C6EF-422D-AA93-5543B188B12EQ34415484-7DBC4E78-DB08-45B0-A88F-DB83978551D0Q34475754-EAF39900-2A41-46A4-BF7E-383B23CD5AD1Q34561518-283F1BCA-AA43-45AC-B327-7B34C556743BQ34571940-6E99FDDC-EAB9-493B-8DD8-027745F67D5BQ34592429-2E870B23-AFDD-4D12-8385-93650A77AFFD
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Richard G Gorlick
@ast
Richard G Gorlick
@en
Richard G Gorlick
@en-gb
Richard G Gorlick
@es
Richard G Gorlick
@nl
Richard G Gorlick
@sl
type
label
Richard G Gorlick
@ast
Richard G Gorlick
@en
Richard G Gorlick
@en-gb
Richard G Gorlick
@es
Richard G Gorlick
@nl
Richard G Gorlick
@sl
prefLabel
Richard G Gorlick
@ast
Richard G Gorlick
@en
Richard G Gorlick
@en-gb
Richard G Gorlick
@es
Richard G Gorlick
@nl
Richard G Gorlick
@sl
P106
P1153
7003393650
P21
P31
P496
0000-0001-8995-2929